Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600129035) titled 'A Prospective, Multicenter, Open-Label Phase IV Clinical Study to Evaluate the Biomarkers, Effectiveness, and Safety Based On A Modified Fixed Dose Regimen of Aflibercept 8mg in Treatment-Naive Patients With Neovascular Age-Related Macular Degeneration (nAMD)' on July 29.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Tianjin Medical University Eye Hospital
Condition:
Untreated nAMD with active subfoveal choroidal neovascularization (CNV), where the total area of CNV accounts for more than 50% of the total lesion area.
Recruitment Status: Not Recruiting
Phase: 2
Date of First ...